← All FAQs
founder-and-team
Who is on the Burna AI advisory board?
The active advisory board spans clinical oncology, pharma and clinical development, federal health IT, regulatory, and clinical informatics, with 20+ advisors. The list below names people who appear in operational contexts such as demos, regulatory discussions, and conference presentation.
Named advisors (sample)
- Dr. Aman Opneja, Chief Trials Officer and Clinical Advisor, multi-drug attribution and Phase 1 oncology trial design.
- Dr. Mary Morison Saltz, CMIO, Stony Brook Cancer Center, data quality at scale and N3C-scale clinical informatics.
- Dr. Stefan Gluck, oncology conference presentation across Europe and the United States, open to fractional CMO path.
- Dr. Usman Shah, Medical Director, GI Oncology and Phase 1 Trials, Atlantic Health System, attribution at the point of clinical encounter.
- Dr. Andrea Pirzkall, Oncology Clinical Development Consultant, former Genentech, BeiGene, Replimune, FDA regulatory strategy and immuno-oncology toxicity.
- Dr. Azita Hamedani, President, UNC Health Faculty Physicians, system design and architectural framing.
- Howard Fingert, FDA credentialing and regulatory pathway authority.
- Joel Saltz, clinical informatics and data infrastructure authority.
- Michel Azoulay, Strategic Advisor to the CEO, Protocol Safe pharma BD discussions.